氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的效果分析

目的：对氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的效果进行分析。方法选取80例高血压合并冠心病患者,随机均分为对照组与观察组（n=40）,对照组采用阿托伐他汀钙片治疗,观察组采用氨氯地平联合阿托伐他汀钙片治疗,对比2组患者心电图以及血压变化。结果2组患者治疗前后舒张压降低较为显著(P＜0.05)。在血压治疗有效概率以及心电图改善有效概率方面,观察组显著优于对照组（P＜0.05）。对照组患者发生不良反应概率为5.00%,观察组为2.50%,2组间差异无统计学意义。结论对于高血压合并冠心病患者采用氨氯地平阿托伐他汀钙片进行治疗,疗效理想、安全、不良反应较小,具有临床应用价值。     

试析氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床价值

目的：探讨氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床价值。方法按照随机原则将于我院接受治疗的88例高血压合并冠心病患者分为观察组与对照组各44例,对照组使用硝苯地平缓释片治疗,观察组予以氨氯地平阿托伐他汀钙片治疗,观察比较2组的治疗效果。结果观察组总有效率为95.45%,高于对照组的77.27%,差异具有统计学意义（P<0.05）;观察组与对照组的不良反应发生率分别为4.55%,18.18%,观察组较对照组低,差异具有统计学意义（P<0.05)。结论氨氯地平阿托伐他汀钙片治疗高血压合并冠心病,临床效果显著,且不良反应少,安全可靠,值得大力推广。     

氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床疗效观察

目的探讨氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床疗效。方法选取天工医院2014-01—2016-01间收治的150例高血压合并冠心病患者,将这150例患者的基本资料输入电脑随机分为对照组和治疗组,各75例。对照组患者给予阿托伐他汀钙片进行治疗,治疗组患者给予氨氯地平阿托伐他汀钙片进行治疗,观察两组患者的临床治疗效果并进行比较。结果治疗组患者治疗后的总有效率94.7%明显优于对照组患者的总有效率85.3%,差异有统计学意义(P<0.05);两组患者治疗前血压、血脂各项指标结果显示无统计学意义(P>0.05),治疗后治疗组患者的血压、血脂各项指标结果明显低于对照组患者,差异有统计学意义(P<0.05);对照组患者共发生5例不良反应,治疗组患者共发生3例不良反应,差异无统计学意义(P>0.05)。结论对高血压合并冠心病患者使用氨氯地平阿托伐他汀钙片治疗的治疗效果非常显著,能够改善患者的血压和血脂指标,同时不良反应较少,临床上值得推广并应用。     

氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的效果分析

目的探讨氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床效果。方法选取2014年4月至2015年8月长葛市人民医院收治的高血压合并冠心病患者80例,随机分成对照组和观察组,每组40例。对照组口服硝苯地平控释片,观察组口服氨氯地平阿托伐他汀钙片,观察两组治疗效果。结果观察组舒张压、收缩压、TG以及LDL-C明显低于对照组,HDL-C明显高于对照组,差异有统计学意义(P<0.05);观察组总有效率(92.50%)明显高于对照组(70.00%),差异有统计学意义(P<0.05)。结论氨氯地平阿托伐他汀钙片可以有效控制高血压合并冠心病患者的血脂、血压水平,缓解病情,提高生活质量。     

氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效观察

目的:探讨氨氯地平阿托伐他汀钙片在高血压合并冠心病患者中的临床疗效。方法:选取2014年1月~2016年2月我院收治的高血压合并冠心病患者80例,随机分为2组各组40例,对照组给予阿托伐他汀钙片,观察组给予氨氯地平阿托伐他汀钙片,对临床疗效及安全性进行评价。结果:观察组治疗总有效率明显高于对照组(95.0%vs80.0%),P0.05,差异存在显著统计学意义;观察组不良反应发生率明显低于对照组(2.5%vs17.5%),P0.05,差异存在显著统计学意义,两组患者不良反应症状轻微未影响治疗,确认可耐受后调整服药剂量或时间完成治疗。结论:氨氯地平阿托伐他汀钙片治疗高血压合并冠心病临床疗效显著且安全性高,值得临床推广。     

氨氯地平阿托伐他汀钙片对高血压合并冠心病的治疗价值探讨

目的 探讨氨氯地平阿托伐他汀钙片对高血压合并冠心病的治疗价值.方法 选取高血压合并冠心病患者80例,随机将80例患者分为对照组和观察组,各40例,对照组予以硝苯地平控释片治疗,观察组予以氨氯地平阿托伐他汀钙片治疗,对比两组患者的治疗结果 .结果观察组的治疗有效率为95.0%,对照组的治疗有效率为75.0%,察组的治疗效果优于对照组(P<0.05);观察组对照组的不良反应分别为10.0%、7.5%,观察组的不良反应情况与对照组相比差异无统计学意义;治疗前两组患者的血压及血脂情况差异无统计学意义;治疗后两组的血压及血脂情况均优于治疗前,且观察组优于对照组,差异具有统计学意义(P<0.05).结论 氨氯地平阿托伐他汀钙片对高血压合并冠心病,能够显著改善患者的血压及血脂情况,且不良反应少,值得临床推广.     

氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的可行性研究

目的:研究高血压合并冠心病使用氨氯地平阿托伐他汀钙片治疗的可行性。方法:将2015年6月至2017年1月在我院接受治疗的高血压合并冠心病94例患者作为研究对象,按照治疗方式将入选患者分为对照组和观察组,对照组44例,使用阿托伐他汀钙片治疗,观察组50例,使用氨氯地平阿托伐他汀钙片治疗,对比观察组和对照组的临床疗效,分析氨氯地平阿托伐他汀钙片是否具有治疗高血压合并冠心病的可行性。结果:观察组患者高血压和冠心病恢复的总有效率96.6%和98.0%,分别高于对照组81.8%和84.1%,两组比较,具有统计学上差异(P0.05)。观察组患者不良反应发生率2.0%低于对照组6.9%,两组比较不具有统计学差异(P0.05)。结论:高血压合并冠心病使用氨氯地平阿托伐他汀钙片治疗能够降低患者的血压和血脂,且不良反应小,治疗效果确切,具有在临床中应用的可行性。     

氨氯地平片联合阿托伐他汀钙片治疗高血压合并冠心病的疗效分析

目的：分析氨氯地平片联合阿托伐他汀钙片治疗高血压合并冠心病的临床效果。方法选取我院2015年1月—2016年1月收治的80例高血压合并冠心病患者为研究对象,随机均分为对照组和干预组,对照组患者服用硝苯地平与阿托伐他汀钙片治疗,干预组患者则联合服用氨氯地平与阿托伐他汀钙片治疗,对比2组患者的治疗效果及不良反应情况。结果干预组患者的治疗效果明显好于对照组,且不良反应例数少于对照组,差异均有统计学意义（P<0.05）。结论氨氯地平片联合阿托伐他汀钙片治疗高血压合并冠心病疗效较好,值得推广。     

氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效观察

目的：探讨氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效。方法选取100例高血压合并冠心病患者,按入院编号将100例患者随机分为观察组和对照组,各50例。观察组口服氨氯地平阿托伐他汀钙片（最大剂量为10 mg,1次/d）治疗,对照组口服硝苯地平缓释片（1次/d,1片/d）治疗。治疗2个月后,比较观察组和对照组患者的治疗效果及不良反应发生情况。结果观察组患者治疗总有效率94.0%与对照组78.0%相比明显较高（P<0.05）。观察组患者治疗后收缩压、舒张压（70.6±4.3）、（123.5±5.3）mmHg与对照组（79.5±5.8）、（139.4±5.2）mmHg相比均明显较低（P<0.05）。观察组患者不良反应发生率2.0%与对照组4.0%相比差异无统计学意义。结论氨氯地平阿托伐他汀钙片治疗高血压合并冠心病能有效缓解患者临床症状,且不良反应少,值得运用。     

探讨氨氯地平阿托伐他汀钙片对高血压合并冠心病的治疗效果

目的探讨氨氯地平阿托伐他汀钙片对高血压合并冠心病的临床治疗效果。方法选取湖南省委机关医院50例高血压合并冠心病患者的临床资料进行回顾性分析,随机将50例患者分成两组对照组和治疗组,对照组采用常规药物进行治疗,治疗组采用氨氯地平阿托伐他汀钙片治疗,观察两组患者在血压、心电和不良反应等指标的差异。结果治疗组在治疗后血压及心电图改善有效率分别为92.00％和88.00％,显著优于对照组的68.00％和56.00％,差异具有统计学意义（P〈0.05）。结论临床中使用氯地平阿托伐他汀钙片治疗高血压合并冠心病,治疗效果显著,安全系数高,值得推广应用。     

Value of D-Dimers in patients with acute aortic dissection

Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P ＜ 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (＞0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P ＜0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P ＜ 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.     

Research of combined liver-kidney transplantation model in rats

Objective： To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods： SD rats served as both donors and recipients. 4℃ sodium lactate Ringer＇s was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava （IVC） inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results： Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion： This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.     

BLOOD PRESSURE CHANGE WITH AGE IN SALT-SENSITIVE TEENAGERS

Objective To observe blood pressure change with age in salt-sensitive teenagers whose salt sensitivity were determined by repeated testing.Methods Salt sensitivity was determined through intravenous infusion of normal saline combined with volume-depletion by oral diuretic furosemide in 55 teenagers. After five years, salt sensitivity was re-examined and subject blood pressure was followed up. Blood pressure changes in salt-sensitive teenagers were compared to that of non-salt sensitive teenagers over five years.Results After 5 years, the repetition rate of salt sensitivity determined by intravenous saline loading is 92.7%. In teenagers with salt sensitivity on the baseline, both the systolic blood pressure increments and increment rates were much higher than non-salt sensitive teenagers (12.7±12.1 mmHg vs. 2.8±5.2 mmHg, P＜ 0.01; 12.2%± 12.0% vs. 2.5% ±4.4%, P＜ 0.001,respectively). There was a similar trend for diastolic blood pressure (8.4 ± 6.4 mmHg vs. 3.7 ± 6.4 mmHg, P = 0.052; 13.2% ±10.6 % vs. 6.8%± 10.1%, P = 0.053, respectively).Conclusions Salt sensitivity determined by intravenous saline loading showed good reproducibility. Blood pressure increments with age were much higher in salt-sensitive teenagers than non-salt sensitive teenagers, especially in terms of systolic blood pressure.     

安心颗粒对急诊经皮冠状动脉介入术后生活质量影响的研究

目的：评价使用安心颗粒对急诊经皮冠状动脉介入术（PPCI）术后生活质量的影响.方法：将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组（术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次）和对照组（仅接受基础药物治疗）.所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表（MIDAS）、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果：入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异（P＞0.05）;出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低（P＜0.05）;组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低（P＜0.05）.两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血（P＞0.05）.两组发生轻度血小板减少症的患者数比较无差异（P＞0.05）.结论：PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.     

The comparative studies of the influences of Urapidil and Nicardipine on sino-atrial node function, atrio-ventricular node function and hemodynamics

Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P＜0.01);the MAP decreased(P＜0.01)and the HR increased drastically(P＜0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.     

Expression of OPGmRNA and ODFmRNA in the patients of hip fracture due to osteoporosis

Objective：To investigate the gene expression of osteoprotegerin（OPG） and osteoclast differentiation factor（ODF） in the bone tissue of patients with hip fracture due to osteoporosis. Methods：OPGmRNA and ODFmRNA in the bone tissue in 50 cases of osteoporosis sufferers（over 50 years old） with hip fracture（Observer Group） and 30 cases of hip facture sufferers with no osteoporosis（Control group） were analyzed with the Semi-Quantitative RT-PCR method. Results：The mRNA expressed of ODF, OPG were both high in the patients with hip fracture. In the control group, the expression of OPG mRNA was observed, while the expression of ODF mRNA was very slight. Conclusion：Aged patients contained all signals including OPG, ODF that are essential for inducing osteoclastogenesis and promoting bone resorption.     

The clinicopathological and immuohistochemical analysis of solid-pseudopapillary tumor of the pancreas： report of 9 cases

Objective：To investigate the clinical features, pathological characteristics and immunophenotype of solid-pseudopapillary tumor of the pancreas（SPTP）. Methods：Nine surgically treated cases of SPTP were retrospectively reviewed. Hematoxylin and Eosin（HE） staining and immunohistochemical staining were used to analyze all cases, and the general clinical data was collected. Results：Six patients were asymptomatic except for a palpable mass. Two patients complained of vague-epigastric pain. One patient appeared jaundice. The tumor was encapsulated and solid tissues alternately with cystic tissues. Histologically, the histological structure of solid portion was pseudopapillary with a fibrovascular core. Tumor cells were uniform and medium-sized which were arranged in sheets ets or nests or pseudopapillary patterns. Immunohistochemical studies demonstrated that SPTP proved positive in vimentin（9/9 cases）, AAT（9/9 cases）, NSE（9/9 cases）, ACT（7/9 cases）, CK20（2/9 cases）, CgA（1/9 cases）, S-100（3/gcases）, PR（4/gcases）, Syn（3/9 cases） and CD56（5/9cases）, negative in CEA and ER. Conclusion：SPTP is a tumor predominantly occurring in young women frequently without special symptoms. This tumor has various characteristical histological patterns with different immunophenotype.     

Dynamic Changes in Serum Estradiol and Progesterone levels in Patients of Premenstrual Syndrome with Adverse Flow of Liver-qi

Objective:To probe into the influence of changes of ovarian hormones on the pathogenesis of the specific sub-type premenstrual syndrome(PMS)and reveal partial microcosmic mechanisms of adverse flow of liver-qi.Methods:Estradiol(E2)and progesterone(P)levels in serum were determined at different phases of menstrual cycle by radioimmunoassay.Results:In the group of PMS with adverse flow of liver-qi.the secretive peak value Of E2 and P at the follicular phase significantly decreased,and the secretive peak value at the luteal phase did not come into being.Conclusions:Low E2 and P secretive peak at the follicular phase and absence of secretive peak at the luteal phase is one of the microcosmic mechanisms of PMS with adverse flow of liver-qi.One of the pathophysiologic mechanisms of specific sub-type PMS is probably the continuous low level of E2and P.     

Real-time Three-dimensional Echocardiography in Assessment of Left Ventricular and Right Ventricular Volumes

Real-time three-dimensional echocardiography (RT3DE)is a new ultrasound technique that enables dynamic threedimensional visualization and quantification of the heart in real time. Investigation of feasibility and methodology of RT3DE in determining left ventricular (LV) and right ventricular (RV) volumes, RT3DE was performed in 35 normal adults using Philips SONOS 7500 system with a 2-4 MHz matrix array transducer. The 60°×60° "pyramid" volume database was obtained and analyzed on a TomTec echo workstation. Both LV and RV volumes were calculated with four 3DE methods (i.e. apical 2, 4, 8, and 16-plane) through manually tracing ventricular endocardial borders in end diastole and end systole. Stroke volumes were then calculated. LV volume was also measured by 2DE Simpson's rule using GE VIVID 7 ultrasound machine.     

SCREENING FOR A 21-CHROMOSOME ABNORMALITY IN PREIMPLANTED EMBRYOS OF ELDERLY WOMEN

Increasing maternal age is the only etiological factor unequivocally linked to Down's syndrome in humans. The occurrence rate of newborns with Down's syndrome is about 1/220 in women over 35 years old. However, the occurrence rate in embryos fertilized in vitro, of the elder woman is unclear. Using FISH we screened the number of chromosome 21 in preimplanted embryos of 5 elderly women (average age, 38.4 years) to study the feasibility and necessity of screening trisomy 21 in embryos in patients over 35 years old at the in vitro fertilization (IVF) center.